Table 1 Characteristics of groups 1 and 2 at acromegaly diagnosis and at baseline     All patients Group 1 PEGV Group 2 PEGV?+?SSA A Patients – n (%) 62 a 35 (56.4) 27 (43.6) T Males 21 (33.9) 11 (31) 10 (37) D Age at diagnosis (y) – median (range) 33 (18–72) 39 (21–72) 31 (18–70) I Patients with macroadenomas – n (%) 50 (83%) 28 (80) 22 (81.5) A Comorbidities – n (%)       G Hypertension 25 (40.3) 15 (42.8) 10 (37) N Diabetes 22 (35.5) 15 (42.8) 7 (25.9) O Cardiomyopathy 23 (37.1)

see more 12 (34.2) 11 (40.7) S Sleep apnea 24 (38.7) 6 (17.1) 18 (66.6)* I Vertebral fractures 16 (25.8) 12 (34.2) 4 (14.8) S Goiter 23 (27.1) 12 (34.2) 11 (40.7) Colon cancer 3 (4.8) 1 (2.8) 2 (7.4) Hypopituitarism – n (%) 27 (43.5) 13 (37.1) 14 (51.8) ACTH deficiency 4 (6.5) 2 (5.7) 2 (7.4) LH/FSH deficiency 25 (40.3) 13 (37.1) 12 (44.4) TSH deficiency 7 (11.3) 5 (14.2) 2 (7.4) Vasopressin deficiency 0 (0) 0 (0) 0 (0) Hyperprolactinemia – n (%) 12 (19.3) 6 (17.1) 6 (22.2) GH nadir – μg/L b       Median (range) 10.25 (2.2-100) 9.4 (2.2-63.1) 17.1 Selleckchem BVD-523 (3.3-100)* Mean (±SD) 22.2 (±23) 16.9 (±17.3) 29 (±27.6)* IGF-I levels       μg/L, Median (range) 715 (315–1587) 670 (315–1210) 899 (425–1587)* SDS (range) 9.9 (2.9-22.2) 8.8 (2.9-22.2) 10.9 (3.6-21.7)* Florfenicol ng/ml, Mean (±SD) 804 (±246) 723 (±216) 906 (±254) A BMI (kg/m2) – median (range) 28.7 (19.1-42) 27

(20–42) 30 (19.1-37.8) T Estimated disease duration (y) – median (range) 5 (2–20) 5 (2–20) 5 (2–20) B Previous treatments – n (%)       A Surgery – n (%) 59 (95.2) 33 (94.2) 26 (96.3) S Residual adenoma 39 (62.9) 17 (51.5) 22 (84.6)* E Somatostatin analogs – n (%) 62 (100) 35 (100) 27 (100) L Duration of Sepantronium concentration treatment (y) – median (range) 4 (2–17) 4 (2–16) 4 (2–17) I Radiotherapy – n (%) 16 (25.8) 7 (20) 9 (33) N Dopamine agonists – n (%) 13 (20.9) 7 (20) 6 (22) E c GH levels – μg/L d       Median (range) 11 (0.8-77) 8.4 (0.8-77) 18 (3.8-74.0)* Mean (±SD) 21.4 (±21) 17.2 (±19.7) 30.9 (±22.5)* IGF-I levels       μg/L , Median (range) 621.5 (431–1621) 632 (431–1621) 592 (455–929)# SDS (range) 6.9 (2.7-19.5) 6.9 (2.7-19.1) 5.9 (3.4-16.5)# μg/L , Mean (±SD) 673(±224) 736 (±258) 661 (±162)# Δ IGF-I e       μg/L , Median (range) 132 (−411-872) 57 (−411-692) 205 (−115-872)* SDS (range) 2 (−5.8-13.4) 0.9 (−5.8-11.2) 3.1 (−1.7-13.4)*   μg/L , Mean (±SD) 131 (±266) 38 (±250) 251 (±241)* The results are shown as median (range) or number (percent), unless otherwise specified.